相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes
Jingyi Lu et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge
Hideaki Kaneto et al.
DIABETES OBESITY & METABOLISM (2020)
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update - The User's Guide
Peter A. Senior et al.
CANADIAN JOURNAL OF DIABETES (2020)
Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study
Ranjit Mohan Anjana et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino et al.
DIABETES CARE (2019)
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Roy W. Beck et al.
DIABETES CARE (2019)
The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes
Robert A. Vigersky et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lorraine Lipscombe et al.
CANADIAN JOURNAL OF DIABETES (2018)
Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes
Jingyi Lu et al.
DIABETES CARE (2018)
Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study)
Harpreet S. Bajaj et al.
DIABETES CARE (2017)
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
Virginia Valentine et al.
DIABETES THERAPY (2017)
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
Virginia Valentine et al.
DIABETES THERAPY (2017)
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
Julio Rosenstock et al.
DIABETES CARE (2016)
The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide
Kristin K. Clemens et al.
Canadian Journal of Diabetes (2015)
South Asians' cardiac medication adherence
Twyla A. Ens et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING (2014)
Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study
S. R. Aravind et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Ethnicity and Sex Affect Diabetes Incidence and Outcomes
Nadia A. Khan et al.
DIABETES CARE (2011)
Comparison of cardiovascular risk profiles among ethnic groups using population health surveys between 1996 and 2007
Maria Chiu et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
Age- and sex-related prevalence of diabetes mellitus among immigrants to Ontario, Canada
Maria Isabella Creatore et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study
H. C. Gerstein et al.
DIABETIC MEDICINE (2006)
分享论文
